1. Huber, W, Schulte, TL, Carson, S, Goldhammer, RE and Vogin, EE (1968). Some chemical and pharmacological properties of a novel anti-inflammatory protein. Toxicol Appl Pharmacol, 12, 308
2. McCord, JM and Fridovich, I (1969). Superoxide dismutase, an enzymatic function for erythrocuprein. J Biol Chem, 244, 6049–6055
3. Huber, W, Nenander-Huber, KB, Saifer, MGP and Dang, PHC (1977). Studies on the clinical and laboratory pharmacology of drug formulations of bovine Cu-Zn superoxide dismutases (orgotein). In: Willoughby, DA, Giroud, JP and Velo GP (Eds), Perspectives in Inflammation, pp. 527–544. (Lancaster: MTP Press)
4. Edsmyr, F, Huber, W and Nenander-Huber, KB (1976). Orgotein efficacy in ameliorating side effects due to radiation therapy: I double-blind, placebo-controlled trial in patients with bladder tumors. Curr Ther Res, 19(2), 198–211
5. Tetsuo, A, Makamoto, F, Yoshimasa, I, Kazuyuki, H, Mamoru, S and Katsuhito, S (1966). Effect of superoxide dismutase on glomerual nephritis. Biochem Pharmacol, 35(2), 341–345